Evaluation of the Onclarity HPV assay on the high-throughput COR system

References

• Molecular diagnostics market report, fortune business insights; 2019. https://www.fortunebusinessinsights.com/industry-reports/molecular-diagnostics-market-100086. December 01, 2020
   Google Scholar
• Public health England guidance – Cervical screening: acceptable HPV tests; 2019. [Cited 2021 Dec 01]. Avaialable from: https://www.gov.uk/government/publications/cervical-screening-acceptable-hpv-tests/cervical-screening-acceptable-hpv-tests
   Google Scholar
• Aretzweiler G, Leuchter S, Simon CO, et al. Generating timely molecular diagnostic test results: workflow comparison of the cobas® 6800/8800 to panther. Expert Rev Mol Diagn. 2019;19(10):951–957.*
   PubMed Web of Science ®Google Scholar
• Oštrbenk Valenčak A, Šterbenc A, Seme K, et al. Alinity m HR HPV assay fulfills criteria for human papillomavirus test requirements in cervical cancer screening settings. J Clin Microbiol. 2019;58(1):e01120–01119.
   PubMed Web of Science ®Google Scholar
• Saville M, Sultana F, Malloy MJ, et al. Clinical validation of the cobas HPV test on the cobas 6800 system for the purpose of cervical screening. J Clin Microbiol. 2019;57(2):e01239–01218.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Use of pap smears among women aged 18 and over, by selected characteristics: United States, selected years 1987–2015; 2015. [Cited 2021 Dec 01]. Available from: https://www.cdc.gov/nchs/hus/contents2018.htm#Table_034
   Google Scholar
• Zhao C, Crothers BA, Ghofrani M, et al. Human papillomavirus genotyping testing practice in 2014: results of a college of American pathologists national survey. Arch Pathol Lab Med. 2016;140(12):1364–1370.
   PubMed Web of Science ®Google Scholar
• Stoler MH, Wright TC, Parvu V, et al. The Onclarity human papillomavirus trial: design, methods, and baseline results. Gynecol Oncol. 2018;149(3):498–505.
   PubMed Web of Science ®Google Scholar
• Stoler MH, Wright TC Jr., Parvu V, et al. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, >/=25years of age, with NILM cytology. Gynecol Oncol. 2019;153(1):26–33.
   PubMed Web of Science ®Google Scholar
• Stoler MH, Wright TC, Parvu V, et al. HPV testing with 16, 18, and 45 genotyping stratifies cancer risk for women with normal cytology. Am J Clin Pathol. 2019;151(4):433–442.
   PubMed Web of Science ®Google Scholar
• Wright TC Jr., Parvu V, Stoler MH, et al. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: results from the baseline phase of the Onclarity trial. Gynecol Oncol. 2019;153(2):259–265.
   PubMed Web of Science ®Google Scholar
• Wright TC Jr., Stoler MH, Parvu V, et al. Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, >/=21 years of age, with ASC-US or LSIL cytology. Gynecol Oncol. 2019;154(2):360–367.
   PubMed Web of Science ®Google Scholar
• Wright TC Jr., Stoler MH, Parvu V, et al. Detection of cervical neoplasia by human papillomavirus testing in an atypical squamous cells-undetermined significance population: results of the Becton Dickinson Onclarity trial. Am J Clin Pathol. 2019;151(1):53–62.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Hyun N, Raine-Bennett TR, et al. A cohort study of cervical screening using partial HPV typing and cytology triage. Int J Cancer. 2016;139(11):2606–2615.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Vaughan LM, Raine-Bennett TR, et al. A study of HPV typing for the management of HPV-positive ASC-US cervical cytologic results. Gynecol Oncol. 2015;138(3):573–578.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Wentzensen N, Perkins RB, et al. An Introduction to the 2019 ASCCP risk-based management consensus guidelines. J Low Genit Tract Dis. 2020;24(2):87–89.
   PubMed Web of Science ®Google Scholar
• Cheung LC, Egemen D, Chen X, et al. 2019 ASCCP risk-based management consensus guidelines. J Low Genit Tract Dis. 2020;24(2):90–101.
   PubMed Web of Science ®Google Scholar
• Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321-346.
   Web of Science ®Google Scholar
• Arbyn M, Snijders PJ, Meijer CJ, et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect. 2015;21(9):817–826.
   PubMed Web of Science ®Google Scholar
• Young S, Vaughan L, Yanson K, et al. Analytical and clinical sample performance characteristics of the Onclarity assay for the detection of human papillomavirus. J Clin Microbiol. 2020;59(1). DOI:10.1128/JCM.02048-20.
   Web of Science ®Google Scholar
• Trevisan A, Schlecht NF, Ramanakumar AV, et al. Human papillomavirus type 16 viral load measurement as a predictor of infection clearance. J Gen Virol. 2013;94(Pt 8):1850–1857.
   PubMedGoogle Scholar
• Ejegod DM. Clinical validation of the BD Onclarity? HPV assay using a non-inferiority test. J Med Microbiol Diagn. 2015;s3. DOI:10.4172/2161-0703.S3-003
   Google Scholar
• Ejegod D, Bottari F, Pedersen H, et al. BD Onclarity HPV assay on samples collected in surepath medium meets the international guidelines for human papillomavirus test requirements for cervical screening. J Clin Microbiol. 2016;54(9):2267–2272.
   PubMed Web of Science ®Google Scholar
• BD Onclarity™ HPV assay for the BD viper LT™ system. CE Mark Instructions for use, Ref 442946; 2019.
   Google Scholar
• BD Onclarity™ HPV assay [package insert]. Becton, Dickinson and Company, Sparks-Glencoe, MD; 2018.
   Google Scholar
• Meijer CJLM, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124(3):516–520.
   PubMed Web of Science ®Google Scholar
• Ejegod DM, Junge J, Franzmann M, et al. Clinical and analytical performance of the BD Onclarity HPV assay for detection of CIN2+ lesions on SurePath samples. Papillomavirus Res. 2016;2:31–37.
   PubMed Web of Science ®Google Scholar
• Wright TC Jr., Stoler MH, Agreda PM, et al. Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens. Am J Clin Pathol. 2014;142(1):43–50.
   PubMed Web of Science ®Google Scholar
• Bottari F, Iacobone AD, Boveri S, et al. Onclarity human papillomavirus extended genotyping in the management of cervical intraepithelial neoplasia 2+ lesions. J Low Genit Tract Dis. 2019;23(1):39–42.
   PubMed Web of Science ®Google Scholar
• Castle PE, Gutierrez EC, Leitch SV, et al. Evaluation of a new DNA test for detection of carcinogenic human papillomavirus. J Clin Microbiol. 2011;49(8):3029–3032.
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Geraets DT, Moore C, et al. Analytical performance of the Onclarity HPV assay using the VALGENT framework. J Clin Microbiol. 2015;53(10):3272–3279.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Nakade K, Orisaka S, et al. Comparison study of BD Onclarity HPV with digene HC2 high-risk HPV DNA test and Roche Cobas 4800 HPV for detecting high-risk human papillomavirus in Japan. Am J Clin Pathol. 2019;151(3):263–269.
   PubMed Web of Science ®Google Scholar
• Arbyn M, Depuydt C, Benoy I, et al. VALGENT: a protocol for clinical validation of human papillomavirus assays. J Clin Virol. 2016;76(Suppl 1):S14–s21.
   PubMedGoogle Scholar
• Bonde J, Ejegod DM, Cuschieri K, et al. The Valgent4 protocol: robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium. J Clin Virol. 2018;108:64–71.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Cadman L, Mesher D, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108(4):908–913.
   PubMed Web of Science ®Google Scholar
• Ogilvie GS, Van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. Jama. 2018;320(1):343–52.
   PubMed Web of Science ®Google Scholar
• Bonde JH, Pedersen H, Quint W, et al. Clinical and analytical performance of the BD Onclarity HPV assay with surepath screening samples from the Danish cervical screening program using the VALGENT framework. J Clin Microbiol. 2020;58(2). DOI:10.1128/JCM.01518-19.
   PubMed Web of Science ®Google Scholar
• Ejegod DM, Serrano I, Cuschieri KS, et al. Clinical validation of the BD Onclarity™ HPV assay using a non-inferiority test. J Med Microb Diagn. 2013;S3:003.
   Google Scholar
• Ejegod DM, Pedersen H, Alzua GP, et al. Time and temperature dependent analytical stability of dry-collected Evalyn HPV self-sampling brush for cervical cancer screening. Papillomavirus Res. 2018;5:192–200.
   PubMed Web of Science ®Google Scholar